News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Iterum Therapeutics plc (ITRM) announced it has resubmitted New Drug Application to the FDA for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in adult women. The NDA resubmission includes data from the REASSURE, SURE1, SURE 2 and SURE 3 phase 3 clinical trials.
The company said, provided that the resubmitted NDA addresses all of the deficiencies identified in the complete response letter the company received from the FDA in July 2021, it expects that the FDA will complete review and take action six months from the date the FDA received the resubmitted NDA.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
